PSMA-derived peptide–major histocompatibility complex complex and T-cell receptor

The **PSMA-derived peptide–major histocompatibility complex complex and T-cell receptor** collectively refers to a molecular target where a short peptide derived from prostate-specific membrane antigen (PSMA), an intracellular or membrane-associated antigen, is processed and presented on the cell surface by a major histocompatibility complex (MHC) molecule. T cells recognize this complex through their T-cell receptor (TCR), enabling highly specific immune targeting of cells presenting PSMA-derived peptides. This molecular axis underpins the rationale behind TCR-based immunotherapies for prostate cancer and other malignancies expressing PSMA. Therapies may use engineered T cells or TCR-mimic antibodies to recognize the PSMA peptide/MHC complex and trigger targeted cell killing. The approach depends on proper antigen processing, MHC genotype, and T cell specificity. Key challenges include tumor heterogeneity in antigen presentation, risk of autoimmune toxicity from TCR cross-reactivity, and tumor immune evasion mechanisms[1][2][5][6]. If you require the exact PSMA-derived peptide or MHC allele, please specify, as multiple PSMA peptides can serve as targets depending on the MHC context and use-case[4]. If you need structured information for only a component (just the T cell receptor or just the pMHC), a refined query can be provided.

Other names

PSMA peptide/MHC complex and TCRTCR:pMHC (T cell receptor:peptide–MHC) complex

Targeted TCRs or TCR-mimics recognize and bind to PSMA-derived peptide presented by MHC on target cells, initiating T cell activation and cytotoxic response against cancer cells[1][2][5]. Some drugs enhance MHC/peptide presentation or alter the immunopeptidome, making PSMA-derived targets more visible to immune effectors[6].